|
(Diaminomethyl-Methyl-Amino)-Acetic Acid
|
DB02490 |
|
|
Pancrelipase lipase
|
DB13147 |
[Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.[L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system.[A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]] |
|
Acetylcysteine zinc
|
DB14479 |
|
|
Povidone K30
|
DB14478 |
[A polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See [povidone] for full details.] |
|
Coagulation factor X human
|
DB13148 |
[Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency.
Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. It is a two-chain glycoprotein with the molecular weight of approximately 59 kDa [A31472]. While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways. Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. Administration of coagulation Factor X from healthy donor serves to restore and achieve effective hemostasis.
Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors who have passed viral screening tests [FDA Label].] |
|
Protein S human
|
DB13149 |
[Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.] |
|
Methallenestril
|
DB13143 |
|
|
L-Lactic acid
|
DB14475 |
|
|
Sorbitan
|
DB14474 |
|
|
Lenograstim
|
DB13144 |
[Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.] |
|
DL-alpha tocopheryl acetate
|
DB14477 |
|
|
Nedaplatin
|
DB13145 |
[Nedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.] |
|
Fluciclovine (18F)
|
DB13146 |
[Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging.[A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.[A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]] |
|
DL-alpha-Tocopherol
|
DB14476 |
|
|
2-Ethylhexyl 4-phenylbenzophenone-2'-carboxylate
|
DB14471 |
|
|
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (propiolactone inactivated)
|
DB14470 |
[A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.] |
|
Bezlotoxumab
|
DB13140 |
[Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence.] |
|
Ambroxol acefyllinate
|
DB13141 |
|
|
Beroctocog alfa
|
DB14473 |
|
|
Insulin-like growth factor II
|
DB14472 |
[The insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth regulation, insulin-like and mitogenic activities. To perform its biological activities, this growth factor can present some dependence to [somatotropin]. It is believed to be a major fetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults.] |
